Evidence map›Paper›PMID 30674471›Full record

ArticleBlood2019

Cécile Esnault, Ramy Rahmé, Kim L Rice, Caroline Berthier, Coline Gaillard, Samuel Quentin, Anne-Lise Maubert, Scott Kogan, Hugues de Thé

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Cell cycle (Georgetown, Tex.) · 2020
    Review
  20. Biomedicines · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Cécile EsnaultINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Ramy RahméINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Kim L RiceINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Caroline BerthierINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Coline GaillardDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA.
Samuel QuentinINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Anne-Lise MaubertINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.
Scott KoganDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA.
Hugues de ThéINSERM U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Paris, France.ORCID 0000-0002-1113-4472
Centre National de la Recherche Scientifique · FRUniversity of California, San Francisco · US

Funding

Molecular Mechanisms of Leukemogenesis by PMLRAR alphaR01CA095274 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOGAN, SCOTT C. · 2002 to 2013
$2.7M
NCI NIH HHS R01 CA095274
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is often associated with activating FLT3 signaling mutations. These are highly related to hyperleukocytosis, a major adverse risk factor with chemotherapy-based regimens. APL is a model for oncogene-targeted therapies:

Indexed as

AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsArsenicFemalefms-Like Tyrosine Kinase 3Leukemia, Promyelocytic, AcuteMice, Inbred C57BLMutationTretinoinAntineoplastic AgentsArsenicFlt3 protein, mousefms-Like Tyrosine Kinase 3Tretinoin

Identifiers

PMID30674471
PMCPMC6440296
OpenAlexW2912682470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.